Discover open access scientific publications

Search, annotate, share and cite publications

Publications by F. Mo

OA07.02 ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases After EGFR TKI

Journal of Thoracic Oncology

English

Correction of X-Ray Intensities for Multiple Diffraction

Acta Crystallographica Section A Foundations of Crystallography

1987

English

Related publications

MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients With EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/Ii Study

Journal of Thoracic Oncology

English

Population-Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to 5 Oligometastases: SABR-5

English

Continued EGFR -TKI With Concurrent Radiation Therapy to Improve Time to Progression in Patients With Locally Progressive Non–small Cell Lung Cancer After Front-Line EGFR -TKI Treatment

International Journal of Radiation Oncology Biology Physics

English

OA07.03 Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC PTS With Oligometastatic or Oligoprogressive Liver Metastases

Journal of Thoracic Oncology

English

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics

Cancer Research

Oncology

2016

English

Comparing the Efficacy of Concurrent EGFR-TKI and Whole-Brain Radiotherapy vs EGFR-TKI Alone as a First-Line Therapy for Advanced EGFR-mutated Non-Small-Cell Lung Cancer With Brain Metastases: A Retrospective Cohort Study

Cancer Management and Research

Oncology

2019

English

PUB047 Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation

Journal of Thoracic Oncology

English

OA07.05 Local Ablative Therapy Improves Survival in Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated With EGFR-TKIs

Journal of Thoracic Oncology

English

PC04.02 Optimal Sequencing of EGFR TKI Therapy - 3rd Generation First

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by F. Mo

OA07.02 ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases After EGFR TKI

Correction of X-Ray Intensities for Multiple Diffraction

Related publications

MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients With EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/Ii Study

Population-Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to 5 Oligometastases: SABR-5

Continued EGFR -TKI With Concurrent Radiation Therapy to Improve Time to Progression in Patients With Locally Progressive Non–small Cell Lung Cancer After Front-Line EGFR -TKI Treatment

OA07.03 Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC PTS With Oligometastatic or Oligoprogressive Liver Metastases

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Comparing the Efficacy of Concurrent EGFR-TKI and Whole-Brain Radiotherapy vs EGFR-TKI Alone as a First-Line Therapy for Advanced EGFR-mutated Non-Small-Cell Lung Cancer With Brain Metastases: A Retrospective Cohort Study

PUB047 Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation

OA07.05 Local Ablative Therapy Improves Survival in Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated With EGFR-TKIs

PC04.02 Optimal Sequencing of EGFR TKI Therapy - 3rd Generation First